Xylitol and the prevention of periodontal disease and preterm birth (XAPPP) trial - preterm birth (PTB) is the leading cause of under-5-year-old mortality and neurodevelopmental impairment worldwide…

Active Grant Awarded Last action

Award ID
R01HD119029
Recipient
Awarding agency
Obligated
$1,145,282

Award facts

Completion date 24% complete
Place of performance
Seattle, WA 98195, USA

Award details come from USAspending.gov.

Description

Xylitol and the prevention of periodontal disease and preterm birth (XAPPP) trial - preterm birth (PTB) is the leading cause of under-5-year-old mortality and neurodevelopmental impairment worldwide and affects between 5-29% of pregnancies. Periodontal disease (PD), including either gingivitis or periodontitis, is a risk factor for PTB. Unfortunately, PTB and PD disproportionately occur in many low- and middle-income countries where access to physicians and dentists is limited. Using a novel inexpensive and non- invasive treatment approach, we recently completed a cluster-randomized trial in malawi entitled the prevention of prematurity and xylitol (PPAX) trial in which we demonstrated that use of xylitol-containing chewing GUM significantly reduced clinical metrics of maternal periodontal disease (P=0.03) and the occurrence of PTB (xylitol 12.6% VS control 16.5%, ARR 0.76, 95% CI 0.59-0.99). Xylitol is a naturally occurring sugar alcohol found in several chewing GUM products and is a prebiotic, known to prevent the growth of periodontopathic bacteria and dampen the pro-inflammatory cascade. As infection and inflammation are risk factors for PTB, xylitol may be a novel, inexpensive innovation that improves maternal and offspring outcomes. While the results of the PPAX trial are promising, we propose to conduct a double-blinded, 3-arm, placebo- controlled trial to address the PPAX trial's limitations and prove the results are reproducible. PPAX trial limitations included: (a) lack of blinding, (B) lack of placebo control, (C) lack of optimized xylitol dosing based on recent evidence that 5-10 grams of xylitol/day is best for oral health benefit, (D) and lack of individual randomization (PPAX was cluster randomized with only 8 clusters). These limitations inflate the risk of spurious findings. The proposed individually randomized trial will enroll N=6000 malawian pregnant individuals at…

Transactions

Action Obligated Date
Amendment $187,566
Amendment $385,325
Amendment $243,610
Original award $328,781

Subawards

Subrecipient Amount Awarded
Baylor College Of Medicine Childrens Foundation Malawi Xylitol and the Prevention of Periodontal disease and Preterm Birth (XaPPP) Trial. $243,610

Quick answers

Who received award R01HD119029?

R01HD119029 was awarded to University Of Washington by National Institute of Child Health and Human Development (National Institutes of Health) on September 12, 2025.

How much is award R01HD119029 worth?

$1,145,282 has been obligated on R01HD119029.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award